Achieve Life Sciences AI Stock Analysis
Achieve Life Sciences (SP4P) AI Stock Analysis
Achieve Life Sciences
(Frankfurt:SP4P)
No summary available
Achieve Life Sciences (SP4P) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 604.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 193
- Price to Earnings (P/E)
- -4.0
- Beta (1Y)
- 1.43
- Revenue Growth
- ―
- EPS Growth
- 5.28%
- Country
- Germany
- Employees
- 28
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Achieve Life Sciences Business Overview & Revenue Model
Company Description
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a...
Achieve Life Sciences Earnings Call Summary
The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Achieve guided that it expects a complete response letter on or by its June 20, 2026 PDUFA date and plans to resubmit the NDA in Q4 2026 naming Adare as primary manufacturer (first Adare engineering batch completed in Q1 2026) with a targeted commercial launch in H1 2027; the company also expects to initiate the ORCA‑V2 vaping Phase III this year under its CNPV and breakthrough designations. Financially, the company closed a financing providing $180 million upfront plus up to $174 million of milestone-based warrants (exercisable any time prior to and up to 20 trading days following FDA approval). Key clinical/operational metrics cited include analysis of >1,600 Phase III participants, two Phase III double‑blind, placebo‑controlled trials in which both 6‑ and 12‑week courses were statistically significant, planned 52‑week safety/efficacy data later this year, and subgroup results showing 12‑week cytisinicline continuous abstinence of 32.4% versus 6% on placebo (OR 7.5); Achieve said it will commercialize independently with a scalable field force and believes its IP extends into the late 2030s/2040s.
Achieve Life Sciences Risk Analysis
Achieve Life Sciences disclosed 69 risk factors in its most recent earnings report. Achieve Life Sciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAchieve Life Sciences Peers Comparison
Overall Rating
OVID52Neutral
AVXL46Neutral
ACIU45Neutral
VNDA40Underperform
NERV38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 52Neutral | $441.63M | -12.50 | -23.38% | ― | -78.05% | 63.85% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $61.88M | -4.02 | -11.43% | ― | ― | 73.28% | |
| 45Neutral | $216.78M | -4.08 | -104.05% | ― | 384.77% | 38.30% | |
| 40Underperform | $221.92M | -0.74 | -106.94% | ― | 8.11% | -222.50% | |
| 38Underperform | $105.65M | -0.08 | 167.68% | ― | ― | -1306.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:SP4P | Achieve Life Sciences | 5.35 | 1.99 | 59.23% | |
| VNDA | Vanda Pharmaceuticals | 3.44 | -1.44 | -29.55% | |
| NERV | Minerva Neurosciences | 2.00 | -1.78 | -47.09% | |
| AVXL | Anavex Life Sciences | 0.59 | -2.49 | -80.81% | |
| ACIU | AC Immune | 1.95 | -1.13 | -36.69% | |
| OVID | Ovid Therapeutics | 2.20 | 0.71 | 47.65% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
